Adoptive Immunotherapy

This is a specific type of immunotherapy where doctors take immune cells from your body, make them stronger against disease, and then put them back in. It's like sending special 'super soldiers' (immune cells) to fight the disease directly. This is often used for certain types of cancer.

Therapy

What people using Adoptive Immunotherapy report

Every report comes from a Lived member, sent anonymously.

Have you tried Adoptive Immunotherapy for Diffuse Large B-Cell Lymphoma?

NameHow it went

About Adoptive Immunotherapy

How It Works

Adoptive immunotherapy, also called adoptive cell therapy or T-cell transfer therapy, treats cancer by using a person's own immune cells as the medicine. T cells, the white blood cells that normally find and kill infected or abnormal cells, are collected, multiplied into very large numbers in a laboratory and then infused back into the bloodstream. The goal is to give the immune system a force that is big enough, and aimed precisely enough, to overcome a cancer it could not control on its own. The best-known form is CAR T-cell therapy. CAR stands for chimeric antigen receptor, a lab-made receptor added to the T cells that lets them lock onto a specific protein on cancer cells, such as CD19 on many leukemia and lymphoma cells or BCMA on myeloma cells. Because the engineered cells keep multiplying inside the body, CAR T therapy is often described as a living drug and is usually given as a single infusion. A second form, tumor-infiltrating lymphocyte (TIL) therapy, starts with T cells taken from the tumor itself, which have already shown some ability to recognize the cancer, and grows them without genetic engineering. A third approved form engineers T cells with a different kind of receptor, called a T-cell receptor (TCR), to recognize a target inside certain sarcoma cells.

Who It's For

In the United States, CAR T-cell therapy is approved for specific blood cancers, mostly when standard treatment has not worked or the cancer has come back. These include certain types of lymphoma (such as large B-cell, follicular and mantle cell lymphoma), B-cell acute lymphoblastic leukemia (ALL) in children, young adults and adults, chronic lymphocytic leukemia and multiple myeloma. For some people with large B-cell lymphoma that returns within a year of first treatment, CAR T is now used as the second treatment rather than being held in reserve. Recognizable products include tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta) and ciltacabtagene autoleucel (Carvykti), and each is approved only for particular cancers and stages. For solid tumors, the approved options are narrower. Lifileucel (Amtagvi), a TIL therapy, is approved for adults with advanced melanoma that has grown after a PD-1 immunotherapy drug (and after targeted pills if the tumor has a BRAF mutation). Afamitresgene autoleucel (Tecelra) is approved for advanced synovial sarcoma, a rare soft-tissue cancer, after chemotherapy, in people whose tumor and tissue type match its target on specific lab tests (a tumor test for the target protein and a blood test for an inherited immune marker). Uses for other solid tumors and for severe autoimmune diseases such as lupus are being studied in clinical trials and remain experimental. Candidates generally need to be well enough to tolerate the preparatory chemotherapy and possible intensive care, and to have a cancer that carries the cell therapy's target.

What It Involves

Treatment takes place at specialized cancer centers with experience in these products. For CAR T therapy, blood is drawn through a process called leukapheresis, in which a machine separates out the white blood cells and returns the rest of the blood. The cells are shipped to a manufacturing laboratory, engineered and grown, then sent back frozen. This usually takes a few weeks, and some people need additional cancer treatment, often called bridging therapy, to keep the disease in check while they wait. For TIL therapy, a surgeon removes part of a tumor so the cells can be grown from it; in the melanoma trial, infusion came about five weeks after tumor removal. A few days before the infusion, a short course of chemotherapy, called lymphodepletion, lowers the number of the person's existing immune cells so the new cells have room to expand. The infusion itself resembles a blood transfusion and usually takes less than an hour. CAR T may be given in the hospital or, at some centers, as an outpatient, with checks at least daily for the first week. TIL therapy is always given in the hospital, followed by several doses of interleukin-2 (IL-2), an immune-stimulating drug, with intensive care available. After a CAR T infusion, people are asked to stay close to the treatment center for at least two weeks and not to drive for at least two weeks, because confusion or sudden drowsiness can develop after the first days.

What to Expect

The most intense period is the first one to two weeks after infusion. Fever is common and is often the first sign that the cells are active. The team checks vital signs, blood counts and alertness frequently, because the main side effects usually begin within the first several days, and someone treated as an outpatient may be admitted if they appear. Recovery takes longer than the hospital stay. Low blood counts can last weeks to months and the immune system stays weakened, so regular blood tests continue after people go home, and some need antibody infusions (immunoglobulin replacement) to lower infection risk. Follow-up tests and scans in the following months show whether the cancer has responded. Responses vary widely: some people go into a long remission after one infusion, some respond and later relapse, and some do not respond.

What the Evidence Says

For some blood cancers, the evidence is strong. CAR T therapy eliminated leukemia in most children and young adults with relapsed B-cell ALL in the trials that led to its approval, and many of them have stayed cancer-free for years. In large B-cell lymphoma that returned or resisted treatment within a year, a randomized trial found that people who received axicabtagene ciloleucel lived longer than those assigned to standard chemotherapy with the aim of a stem cell transplant. In large B-cell lymphoma that had resisted several earlier treatments, more than 30% of participants in one CAR T trial were alive with no evidence of cancer five years later. For solid tumors, the evidence is earlier. In the lifileucel melanoma study, about 31% of people had their tumors shrink substantially, and a small minority had complete responses. That approval was granted on the basis of tumor response, and a confirmatory trial is required to confirm its clinical benefit. In autoimmune disease, small studies of CAR T in people with very severe, treatment-resistant illness have reported striking remissions, but they involve few patients and short follow-up and are not yet a basis for routine use.

Risks & Considerations

The two signature risks of CAR T therapy come from the immune activation it is designed to create. Cytokine release syndrome (CRS) happens when activated cells flood the blood with inflammatory messengers, causing fever, chills, a fast heartbeat, low blood pressure and sometimes trouble breathing. Many people who receive CAR T for lymphoma, and with some products most, have some degree of CRS, and in a minority it is severe or, rarely, fatal. TCR therapy (Tecelra) can also cause CRS, although neurologic side effects are less common with it, so the warning signs below apply after either kind of infusion. Neurologic side effects, called immune effector cell-associated neurotoxicity syndrome (ICANS), can cause confusion, trouble speaking or finding words, tremor, unusual sleepiness and, less often, seizures or brain swelling, sometimes after the fever has passed. With some myeloma cell therapies, such as Carvykti, nerve or movement problems can appear weeks to months later and should be reported. Both are treatable, which is why monitoring is so close: CRS most often with tocilizumab (Actemra), a drug that blocks one inflammatory messenger, together with steroids, and neurologic side effects mainly with steroids. After discharge, any fever, chills, dizziness, shortness of breath, confusion, difficulty speaking, unusual sleepiness or shaking needs an immediate call to the treatment team's 24-hour number, and a seizure, loss of consciousness or severe trouble breathing needs emergency care. Infection risk stays high for months because blood counts can remain low and CAR T cells that target CD19 or BCMA also wipe out the normal B cells that make antibodies. Rarely, new T-cell cancers have developed after CD19 and BCMA CAR T therapy, so long-term follow-up is part of care. TIL therapy has a different profile, driven largely by the high-dose IL-2 and preparatory chemotherapy: prolonged low blood counts, serious infections, and heart, lung and kidney strain that can require intensive care, and treatment-related deaths have occurred. There are practical hurdles too. Manufacturing takes weeks, occasionally fails, and the cancer can progress in the meantime. Treatment usually means travel to a specialized center, help from family or friends through the weeks after infusion, and very high costs that depend on insurance approval.

Questions to Ask Your Doctor

  1. 1.Is my cancer one that an approved cell therapy targets, and how would it compare with my other options, including a clinical trial?
  2. 2.What happens while my cells are being made, and will I need treatment to control the cancer during that wait?
  3. 3.Will I be treated as an inpatient or outpatient, how long do I need to stay near the center, and what support will my caregiver need to provide?
  4. 4.Which symptoms should we call about after I go home, and what is the number to reach the team at any hour?
  5. 5.What follow-up will I need for infections, blood counts, antibody levels and vaccinations in the months afterward?

Last reviewed • Oct 2026

Educational content, not medical advice.